Literature DB >> 10376798

Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy.

M Korbelik1, I Cecic.   

Abstract

Selective depletion or inactivation of specific myeloid populations (neutrophils, macrophages) and lymphoid populations (helper T cells, cytolytic T cells) in EMT6 sarcoma-bearing mice was used to determine the contribution of each of these host immune cell types to the curative outcome of Photofrin-based photodynamic therapy (PDT). Immunodepletion of neutrophils and cytolytic T cells initiated immediately after PDT resulted in a marked reduction in PDT-mediated tumor cures. Significant reduction in the cures of EMT6 tumors was also achieved by immunodepletion of helper T cells and inactivation of macrophages by silica treatment. The initial tumor ablation by PDT was not affected by any of the above depletion treatments. These results provide direct evidence that the contribution of neutrophils, macrophages and T lymphocytes is essential for the maintenance of long-term control of PDT-treated tumors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10376798     DOI: 10.1016/s0304-3835(98)00349-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  31 in total

1.  Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

Authors:  Eleonora Reginato; Peter Wolf; Michael R Hamblin
Journal:  World J Immunol       Date:  2014-03-27

Review 2.  Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies.

Authors:  Mans Broekgaarden; Ruud Weijer; Thomas M van Gulik; Michael R Hamblin; Michal Heger
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

Review 3.  Photodynamic therapy for pancreatic and biliary tract carcinoma.

Authors:  Lakshmana Ayaru; Stephen G Bown; Stephen P Pereira
Journal:  Int J Gastrointest Cancer       Date:  2005

Review 4.  Photodynamic therapy of cancer: an update.

Authors:  Patrizia Agostinis; Kristian Berg; Keith A Cengel; Thomas H Foster; Albert W Girotti; Sandra O Gollnick; Stephen M Hahn; Michael R Hamblin; Asta Juzeniene; David Kessel; Mladen Korbelik; Johan Moan; Pawel Mroz; Dominika Nowis; Jacques Piette; Brian C Wilson; Jakub Golab
Journal:  CA Cancer J Clin       Date:  2011-05-26       Impact factor: 508.702

5.  IL-6 potentiates tumor resistance to photodynamic therapy (PDT).

Authors:  Craig M Brackett; Barbara Owczarczak; Kimberley Ramsey; Patricia G Maier; Sandra O Gollnick
Journal:  Lasers Surg Med       Date:  2011-09       Impact factor: 4.025

Review 6.  Neutrophil-Based Drug Delivery Systems.

Authors:  Dafeng Chu; Xinyue Dong; Xutong Shi; Canyang Zhang; Zhenjia Wang
Journal:  Adv Mater       Date:  2018-03-26       Impact factor: 30.849

Review 7.  The Course of Immune Stimulation by Photodynamic Therapy: Bridging Fundamentals of Photochemically Induced Immunogenic Cell Death to the Enrichment of T-Cell Repertoire.

Authors:  Shubhankar Nath; Girgis Obaid; Tayyaba Hasan
Journal:  Photochem Photobiol       Date:  2019-11-10       Impact factor: 3.421

Review 8.  Enhancement of anti-tumor immunity by photodynamic therapy.

Authors:  Sandra O Gollnick; Craig M Brackett
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

Review 9.  The biology of the combretastatins as tumour vascular targeting agents.

Authors:  Gillian M Tozer; Chryso Kanthou; Charles S Parkins; Sally A Hill
Journal:  Int J Exp Pathol       Date:  2002-02       Impact factor: 1.925

10.  Enzyme-activatable imaging probe reveals enhanced neutrophil elastase activity in tumors following photodynamic therapy.

Authors:  Soumya Mitra; Kshitij D Modi; Thomas H Foster
Journal:  J Biomed Opt       Date:  2013-10       Impact factor: 3.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.